Ausgabe 3/2008
Special issue: Biomarkers of Clinical Trials Using Molecular Inhibitors and Radiotherapy: State-of-the-Art Approaches, Guest Editor: Robert G. Bristow
Inhalt (17 Artikel)
Clinical trials and biomarker development with molecularly targeted agents and radiotherapy
Neesha Dhani, Lillian L. Siu
Molecular markers of radiation-related normal tissue toxicity
Paul Okunieff, Yuhchyau Chen, David J. Maguire, Amy K. Huser
Practical approaches to proteomic biomarkers within prostate cancer radiotherapy trials
Eva Christensen, Kenneth R. Evans, Cynthia Ménard, Melania Pintilie, Robert G. Bristow
Clinical biomarkers of kinase activity: examples from EGFR inhibition trials
Mechthild Krause, Michael Baumann
Clinical target promiscuity: lessons from ras molecular trials
Ramesh Rengan, Keith A. Cengel, Stephen M. Hahn
Clinical biomarkers of angiogenesis inhibition
Aaron P. Brown, Deborah E. Citrin, Kevin A. Camphausen
Use of palliative radiotherapy trials for clinical biomarker development
Jonathan Wan, Michael Milosevic, Anthony M. Brade
Biomarkers for DNA DSB inhibitors and radiotherapy clinical trials
Stanley K. Liu, Peggy L. Olive, Robert G. Bristow
Multiple biomarker tissue microarrays: bioinformatics and practical approaches
Søren M. Bentzen, Francesca M. Buffa, George D. Wilson
NON-THEMATIC REVIEW
Pancreatic cancer: from molecular pathogenesis to targeted therapy
Alexios Strimpakos, Muhammad W. Saif, Kostas N. Syrigos
NON-THEMATIC REVIEW
The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host
Osvaldo L. Podhajcer, Lorena Benedetti, Maria Romina Girotti, Federico Prada, Edgardo Salvatierra, Andrea S. Llera